BioLight invests in D.E.S Diagnostics Ltd., a company engaged in develping a unique stick that enables diagnosis and monitoring treatment of Dry Eye Syndrome

BioLight announced today that it is expanding its Glaucoma and Dry Eye Syndrome Cluster by means of investing, through a wholly owned subsidiary, in D.E.S. Diagnostics Ltd., which is developing an innovative stick that enables diagnosis and monitoring of Dry Eye Syndrome by examining various parameters in tear fluid.

Link to the complete article

Link to Newsroom

Comments are closed